FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder

Now, right on the heels of the FDA's approval for a new overdose rescue medication, the agency has cleared Braeburn’s Brixadi (buprenorphine) for use in patients with moderate to severe opioid use disorder.